tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

JSPR Stock Latest News

Jasper Therapeutics Holds Annual Stockholders Meeting
Company AnnouncementsJasper Therapeutics Holds Annual Stockholders Meeting
2d ago
8K
JSPR
Promising Efficacy and Safety in Jasper Therapeutics’ SPOTLIGHT Trial Supports Buy Rating
PremiumRatings
Promising Efficacy and Safety in Jasper Therapeutics’ SPOTLIGHT Trial Supports Buy Rating
19d ago
JSPR
Promising Potential of Jasper Therapeutics’ Briquilimab Drives Buy Rating
PremiumRatings
Promising Potential of Jasper Therapeutics’ Briquilimab Drives Buy Rating
19d ago
JSPR
Jasper Therapeutics Reports Positive Phase 1b/2a Study Results
PremiumCompany Announcements
Jasper Therapeutics Reports Positive Phase 1b/2a Study Results
19d ago
8K
JSPR
Jasper Therapeutics presents data from SPOTLIGHT Phase 1b/2a study
PremiumThe Fly
Jasper Therapeutics presents data from SPOTLIGHT Phase 1b/2a study
20d ago
JSPR
Buy Rating for Jasper Therapeutics: Potential Breakthrough with Briquilimab in CSU Market
PremiumRatingsBuy Rating for Jasper Therapeutics: Potential Breakthrough with Briquilimab in CSU Market
1M ago
JSPR
Jasper Therapeutics price target lowered to $65 from $80 at Oppenheimer
Premium
The Fly
Jasper Therapeutics price target lowered to $65 from $80 at Oppenheimer
2M ago
JSPR
Jasper Therapeutics price target lowered to $33 from $38 at UBS
Premium
The Fly
Jasper Therapeutics price target lowered to $33 from $38 at UBS
2M ago
JSPR
Promising Advancements in Jasper Therapeutics’ Briquilimab Programs Highlight Market Potential
PremiumRatings
Promising Advancements in Jasper Therapeutics’ Briquilimab Programs Highlight Market Potential
2M ago
JSPR
Positive Outlook for Jasper Therapeutics: Promising Clinical Developments and Strategic Updates Support Buy Rating
PremiumRatings
Positive Outlook for Jasper Therapeutics: Promising Clinical Developments and Strategic Updates Support Buy Rating
2M ago
JSPR
Jasper Therapeutics Faces Financial Challenges Amid Rising R&D Costs
PremiumCompany Announcements
Jasper Therapeutics Faces Financial Challenges Amid Rising R&D Costs
2M ago
JSPR
Jasper Therapeutics reports Q1 EPS ($1.41), consensus ($1.48)
PremiumThe Fly
Jasper Therapeutics reports Q1 EPS ($1.41), consensus ($1.48)
2M ago
JSPR
JSPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsJSPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
JSPR
Jasper Therapeutics Signs New Sales Agreement with Jefferies
Premium
Company Announcements
Jasper Therapeutics Signs New Sales Agreement with Jefferies
4M ago
8K
JSPR
Jasper Therapeutics files $300M mixed securities shelf
Premium
The Fly
Jasper Therapeutics files $300M mixed securities shelf
4M ago
JSPR
Promising Innovations in Chronic Urticaria Treatment Drive Buy Rating for Jasper Therapeutics
PremiumRatings
Promising Innovations in Chronic Urticaria Treatment Drive Buy Rating for Jasper Therapeutics
4M ago
JSPR
Positive Outlook for Jasper Therapeutics: Buy Rating Affirmed on Promising BEACON Study Data and Strategic Milestones
PremiumRatings
Positive Outlook for Jasper Therapeutics: Buy Rating Affirmed on Promising BEACON Study Data and Strategic Milestones
4M ago
JSPR
Positive Outlook on Jasper Therapeutics: Sustained Efficacy and Safety of Briquilimab in CSU Treatment
PremiumRatings
Positive Outlook on Jasper Therapeutics: Sustained Efficacy and Safety of Briquilimab in CSU Treatment
4M ago
JSPR
Promising Outlook for Jasper Therapeutics: Buy Rating Amidst Potential Upside and Strategic Developments
PremiumRatings
Promising Outlook for Jasper Therapeutics: Buy Rating Amidst Potential Upside and Strategic Developments
4M ago
JSPR
Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study
PremiumThe FlyJasper Therapeutics presents updated data from Phase 1b/2a BEACON study
4M ago
JSPR
Buy Recommendation for Jasper Therapeutics: Promising Developments in Briquilimab’s Phase 2b Program
Premium
Ratings
Buy Recommendation for Jasper Therapeutics: Promising Developments in Briquilimab’s Phase 2b Program
4M ago
JSPR
Promising Outlook for Jasper Therapeutics: Buy Rating Backed by Briquilimab’s Clinical Progress and Financial Stability
Premium
Ratings
Promising Outlook for Jasper Therapeutics: Buy Rating Backed by Briquilimab’s Clinical Progress and Financial Stability
4M ago
JSPR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >